Home

Intelligence

Services

Subscriptions

News

About Us

Sign In

 

Document Preview

License and Supply Agreement

 

Click "Add to Cart" button to purchase document. 
Documents are emailed immediately after purchase. 
You can also browse documents by title, category, or company... or click here for help finding documents.

 

Title:

License and Supply Agreement

Entities:

Putnam Global Equity Fund

Date:

2007

Size:

116KB total

Price:

$47

ID:

#2764455

 

 

► Business ► Supply ► License & Supply Agreements

 

 

Start of Preview

 
 

 
 
LICENSE AND SUPPLY AGREEMENT
 
 

 
 

 
 
Between
 
 

 
 

 
 
CYTOPHARM, INC.
 
 

 
 
&
 
 

 
 
AMARILLO BIOSCIENCES, INC.
 
 

 
 

 
 

 
 

 
 

 
 
November 16, 2006
 
 

 
 

 
 

 

****Indicates that a portion of the text has been omitted and filed separately with the Commission
CONFIDENTIAL
1

 
TABLE OF CONTENTS
ARTICLE I: DEFINITIONS
5
 
 
ARTICLE II:  RESEARCH AND DEVELOPMENT
12
            Section 2.01.  ABI Obligations
12
            Section 2.02.  CYTO Obligations
13
            Section 2.03.  Availability of Resources; Corporation
14
            Section 2.04.  Reporting Obligations of CYTO
14
 
 
ARTICLE III:  LICENSE
14
            Section 3.01.  License and Supply Grant
14
            Section 3.02.  Restrictions.
15
            Section 3.03.  Retained Rights
15
            Section 3.04.  First Right of Refusal
15
 
 
ARTICLE IV:  PAYMENTS AND ROYALTIES
15
            Section 4.01.  Initial Fee
15
            Section 4.02.  Royalty Payments
16
            Section 4.03.  Milestone Payments
16
            Section 4.04.  Minimum Royalty
16
            Section 4.05.  Reports
16
            Section 4.06.  Records and Audits
17
            Section 4.07.  Exchange Rate; Manner and Place of Payment
17
            Section 4.08.  Late Payments
18
            Section 4.09.  Taxes
18
 
 
ARTICLE V:  TERM AND TERMINATION
18
            Section 5.01.  Term
18
            Section 5.02.  Termination by CYTO
18
            Section 5.03.  Termination by ABI
18
            Section 5.04.  Termination Upon Certain Events
19
            Section 5.05.  Remedies
20
            Section 5.06.  Effect of Termination
20
            Section 5.07.  Bankruptcy
20
            Section 5.08.  Continuing Obligations
21
            Section 5.09.  Return of Confidential Information
21
 
 
ARTICLE VI:  SUPPLY, MANUFACTURE AND PURCHASE OF PRODUCT
21
            Section 6.01.  Supply of Product and Bulk Interferon
21
            Section 6.02.  Supply of Manufacturing Rights
21
            Section 6.03.  Quality Assurance
22
            Section 6.04.  ABI's Duties
22
            Section 6.05.  CYTO's Duties if Manufacturing
23
            Section 6.06.  Failure to Supply
23
 
****Indicates that a portion of the text has been omitted and filed separately with the Commission
CONFIDENTIAL
2
            Section 6.07.  Allocation
24
            Section 6.08.  Records and Audits
24
 
 
ARTICLE VII:  PURCHASE AND <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" />SALE
24
            Section 7.01.  Purchase Price and Payment
24
            Section 7.02.  Labeling and Artwork
25
            Section 7.03.  Purchase Forms
25
            Section 7.04.  Confirmation
25
            Section 7.05.  Delivery
25
            Section 7.06.  Forecasts and Orders
26
 
 
ARTICLE VIII:  WARRANTY, REJECTION AND INSPECTIONS
27
            Section 8.01.  ABI Warranty
27
            Section 8.02.  Rejection of Product for Failure to Conform to Specifications
27
            Section 8.03.  CYTO Inspections
28
 
 
ARTICLE IX:  REGULATORY COMPLIANCE
28
            Section 9.01.  Maintenance of Marketing Authorizations
28
            Section 9.02.  Adverse Drug Event Reporting and Phase IV Surveillance
28
            Section 9.03.  Commercial Sale Testing and Reporting
29
            Section 9.04.  Assistance
29
            Section 9.05.  Compliance
30
 
 
ARTICLE X:  REPRESENTATIONS, WARRANTIES AND COVENANTS
30
            Section 10.01. Corporate Power
30
            Section 10.02. Due Authorization
30
            Section 10.03.  Binding Obligation
30
            Section 10.04. Ownership of ABI Rights
30
            Section 10.05. Material Agreements
31
            Section 10.06. Adverse Properties
31
            Section 10.07. Preservation of Name and Reputation
31
            Section 10.08. Debarment
31
            Section 10.09. Limitation on Warranties
32
            Section 10.10. Limitation of Liability
32
 
 
ARTICLE XI:  PATENTS AND TRADEMARK
32
            Section 11.01.  Filing, Maintenance and Protection of Patents
32
 
 
ARTICLE XII:  COVENANTS OF CYTO AND ABI
32
            Section 12.01. Access to Books and Records
32
            Section 12.02. Further Actions
32
            Section 12.03. Equitable Relief
33
 
 
****Indicates that a portion of the text has been omitted and filed separately with the Commission
CONFIDENTIAL
3
 
 
ARTICLE XIII INDEMNIFICATION
33
            Section 13.01. CYTO Indemnified by ABI
33
            Section 13.02. ABI Indemnified by CYTO
33
            Section 13.03. Prompt Notice Required
34
            Section 13.04. Indemnitor May Settle
34
 
 
ARTICLE XIV:  DISPUTE RESOLUTION
35
            Section 14.01.  Disputes
35
            Section 14.02. Trial Without Jury
35
            Section 14.03. Performance to Continue
35
            Section 14.04. Provisional Remedies
35
            Section 14.05. Determination of Patents and Other Intellectual Property.
35
 
 
ARTICLE XV:  CONFIDENTIALITY
36
            Section 15.01. Confidentiality
36
            Section 15.02. Publicity Review
36
 
 
ARTICLE XVI:  MISCELLANEOUS
37
            Section 16.01. Commercially Reasonable Efforts
37
            Section 16.02. Notices
37
            Section 16.03. Severability
37
            Section 16.04. Entire Agreement/Merger
38
            Section 16.05. Amendment
38
            Section 16.06. Counterparts
38
            Section 16.07. No Waiver of Rights
38
            Section 16.08. Force Majeure
39
            Section 16.09. Further Assurances
39
            Section 16.10. Assignment and Sublicense
39
            Section 16.11. Expenses
39
            Section 16.12. Binding Effect
39
            Section 16.13. Governing Law
40
            Section 16.14. Survival of Representations and Warranties
40
            Section 16.15. No Strict Construction
40
            Section 16.16. Independent Contractors.
40
 
Exhibit I - HBL License and Supply Agreement
 
Exhibit II - PPM License Agreement
 
Exhibit III - ISI License Agreement
 
Exhibit IV - TAMU License Agreement
 
Exhibit V - Specifications
 
Exhibit VI - Certificate of Compliance
 

****Indicates that a portion of the text has been omitted and filed separately with the Commission
CONFIDENTIAL
4

 
LICENSE AND SUPPLY AGREEMENT
 
 
This License and Supply Agreement (Agreement) is made as of November 16, 2006 (the Effective Date), by and between CytoPharm, Inc., (CYTO), a corporation, having a principal place of business at 6 F No. 6, Jungshing Road, Sec. 1, Wugu Shiang, Taipei County 248, Taiwan, and Amarillo Biosciences, Inc., a Texas corporation (ABI), with its principal place of business located at 4134 Business Park Drive, Amarillo, Texas 79110, USA. ABI and CYTO are sometimes referred to collectively herein as the Parties and individually as a Party.
 
 
WHEREAS, ABI has substantial expertise in the oral use of human interferon alpha (IFN) and have proprietary rights and Know-How in the field of formulation of oral IFN;
 
 
WHEREAS, ABI is willing to disclose to CYTO the ABI Know-How consisting of human clinical data and all other data, including but not limited to, safety, bioavailability, and clinical trial data necessary for CYTO to obtain regulatory approval for a product for the treatment of human diseases in the Territory; and

 

End of Preview

 

Home        Intelligence        Services